文献速递真菌感染艾滋病与性传播感染

每日脂质体两性霉素B与每日脱氧胆酸两性霉素B治疗隐球菌性脑膜炎的早期杀菌活性与死亡率比较

Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该研究分析了3项临床研究共498例HIV相关隐球菌性脑膜炎患者,比较每日脂质体两性霉素B 3 mg/kg联合氟胞嘧啶与脱氧胆酸两性霉素B 0.7-1.0 mg/kg联合氟胞嘧啶的诱导治疗。结果显示两组脑脊液早期杀菌活性无统计学差异(P=0.13),10周死亡率在调整基线特征后亦无统计学差异(调整HR 0.74,95%CI 0.44-1.25,P=0.26)。

要点

  • 脂质体两性霉素B组平均EFA为0.495 log10 CFU/mL/day,脱氧胆酸组为0.402,差异无统计学意义(P=0.13)。
  • 10周死亡率脂质体两性霉素B组28.2%,脱氧胆酸组34.6%,调整后HR 0.74(95%CI 0.44-1.25,P=0.26)。
  • 每日脂质体两性霉素B联合氟胞嘧啶诱导治疗显示出与脱氧胆酸两性霉素B相似的脑脊液真菌清除率和10周死亡率。

核心结论

  • 每日脂质体两性霉素B联合氟胞嘧啶诱导治疗HIV相关隐球菌性脑膜炎,其脑脊液真菌清除率和10周死亡率与脱氧胆酸两性霉素B联合氟胞嘧啶相似。

研究设计与样本

  • 分析3项临床研究的数据,纳入498例接受诱导治疗的HIV相关隐球菌性脑膜炎患者,其中脂质体两性霉素B组94例(3 mg/kg/day联合氟胞嘧啶100 mg/kg/day),脱氧胆酸两性霉素B组404例(0.7-1.0 mg/kg/day联合氟胞嘧啶100 mg/kg/day)。
  • 201例有可用的脑脊液早期杀菌活性(EFA)数据(脂质体两性霉素B组46例,脱氧胆酸两性霉素B组155例)。

主要发现

  • 脂质体两性霉素B组平均EFA为0.495(95%CI 0.355-0.634)log10 CFU/mL/day,脱氧胆酸两性霉素B组为0.402(95%CI 0.360-0.445)log10 CFU/mL,无统计学证据表明两组抗真菌活性存在差异(P=0.13)。
  • 10周死亡率脂质体两性霉素B组为28.2%,脱氧胆酸两性霉素B组为34.6%,趋势较低但调整基线特征后无统计学差异(调整HR 0.74,95%CI 0.44-1.25,P=0.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on the antifungal activity of daily liposomal amphotericin B with flucytosine induction regimens for cryptococcal meningitis, which are recommended in high-income countries. Liposomal amphotericin B monotherapy at 3 mg/kg previously failed to meet noninferiority criteria compared to amphotericin B deoxycholate in its registrational clinical trial. We aimed to compare the quantitative antifungal activity and mortality between daily amphotericin B deoxycholate and daily liposomal amphotericin B among persons with human immunodeficiency virus (HIV)-related cryptococcal meningitis receiving adjunctive flucytosine 100 mg/kg/day. METHODS: We analyzed data from 3 clinical studies involving participants with HIV-associated cryptococcal meningitis receiving either daily liposomal amphotericin B at 3 mg/kg/day with flucytosine (n = 94) or amphotericin B deoxycholate at 0.7-1.0 mg/kg/day with flucytosine (n = 404) as induction therapy. We compared participant baseline characteristics, cerebrospinal fluid (CSF) early fungicidal activity (EFA), and 10-week mortality. RESULTS: We included 498 participants in this analysis, of whom 201 had available EFA data (n = 46 liposomal amphotericin B; n = 155 amphotericin B deoxycholate). Overall, there is no statistical evidence that the antifungal activity of liposomal amphotericin B (mean EFA, 0.495 [95% confidence interval {CI}, .355-.634] log10 colony-forming units [CFU]/mL/day) differ from amphotericin B deoxycholate (mean EFA, 0.402 [95% CI, .360-.445] log10 CFU/mL) (P = .13). Mortality at 10 weeks trended lower for liposomal amphotericin B (28.2%) versus amphotericin B deoxycholate (34.6%) but was not statistically different when adjusting for baseline characteristics (adjusted hazard ratio, 0.74 [95% CI, .44-1.25]; P = .26). CONCLUSIONS: Daily liposomal amphotericin B induction demonstrated a similar rate of CSF fungal clearance and 10-week mortality as amphotericin B deoxycholate when combined with flucytosine for the treatment of HIV-associated cryptococcal meningitis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kimuda S, Kwizera R, Dai B, et al. Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis. Clin Infect Dis. 2025. PMID: 38943665. doi:10.1093/cid/ciae326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。